Clinical Trials
36 trialsA Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Pancreas
National Health Research Institutes, Taiwan
ACPC
Jinling Hospital, China
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
The First Affiliated Hospital with Nanjing Medical University
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
Taiho Oncology, Inc.
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
Taiho Oncology, Inc.
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
SOLAR
National Health Research Institutes, Taiwan
S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer
Zhejiang University
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
TTY Biopharm
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Fudan University
Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
NAPAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer
Zhejiang Provincial People's Hospital
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Japan Adjuvant Study Group of Pancreatic Cancer
Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer
Changhai Hospital
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
University of California, San Francisco
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
National Taiwan University Hospital
Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
Fudan University
Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )
Harbin Medical University
ASAGPAC
Peking University
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
Capital Medical University
Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer
Osaka Medical Center for Cancer and Cardiovascular Diseases
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Hallym University Medical Center
IFCSLAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
Chinese PLA General Hospital
S-1 Pancreas
Sanofi
Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis
Fudan University
APC-S1
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
GEM vs GEM+TS-1 for Advanced Pancreatic Cancer
Japan Clinical Cancer Research Organization
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hokkaido Gastrointestinal Cancer Study Group
Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer
Hamamatsu University